Chronic Hepatitis B clinical trials
9 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
- A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
- Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
- Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
- Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
- Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
- A Long-term Observational Study in Participants Who Have Received PBGENE-HBV
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Chronic Hepatitis B” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.